We have located links that may give you full text access.
English Abstract
Journal Article
[The possibility of correcting oxidative stress in patients with inflammatory type of chronic abacterial prostatitis (chronic pelvic pain syndrome category IIIa)].
Urologii︠a︡ 2023 December
INTRODUCTION: The term "chronic prostatitis" includes many different symptomatic patterns, many aspects of which still remain a mystery. The role of oxidative stress in the pathophysiology of many diseases, including prostatitis, is undisputable.
AIM: To evaluate the capabilities of a mineral-vitamin antioxidant complex for the treatment of patients with chronic abacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS).
MATERIAL AND METHODS: A total of 47 patients with inflammatory type of chronic abacterial prostatitis/chronic pelvic pain syndrome (CPPS) were included in the study. The examination, along with standard tests, included evaluation of the antioxidant status. Patients were randomized into the main group (n=26), and the control group (n=21). All men received standard therapy. However, in the main group, Selzinc-plus was additionally prescribed, 2 tablets per day for 2 months. The results were assessed after 2 months of therapy.
RESULTS: Standard therapy had a significant effect in patients of both groups, which lasted for two months. However, additional antioxidant therapy practically doubled this effect on the symptom scale, although it had no influence on the number of leukocytes in the expressed prostate secretions. At baseline, all patients in both groups had a decrease in antioxidant protection. Two months of taking Selzinc-plus led to normalization of the overall antioxidant status. In the control group, there was also a positive trend in antioxidant status, but significant differences were obtained only in the activity of erythrocyte superoxide dismutase.
CONCLUSION: CP/CPPS is accompanied by oxidative stress. Taking Selzinc-plus for two months allows to restore the activity of the antioxidant system.
AIM: To evaluate the capabilities of a mineral-vitamin antioxidant complex for the treatment of patients with chronic abacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS).
MATERIAL AND METHODS: A total of 47 patients with inflammatory type of chronic abacterial prostatitis/chronic pelvic pain syndrome (CPPS) were included in the study. The examination, along with standard tests, included evaluation of the antioxidant status. Patients were randomized into the main group (n=26), and the control group (n=21). All men received standard therapy. However, in the main group, Selzinc-plus was additionally prescribed, 2 tablets per day for 2 months. The results were assessed after 2 months of therapy.
RESULTS: Standard therapy had a significant effect in patients of both groups, which lasted for two months. However, additional antioxidant therapy practically doubled this effect on the symptom scale, although it had no influence on the number of leukocytes in the expressed prostate secretions. At baseline, all patients in both groups had a decrease in antioxidant protection. Two months of taking Selzinc-plus led to normalization of the overall antioxidant status. In the control group, there was also a positive trend in antioxidant status, but significant differences were obtained only in the activity of erythrocyte superoxide dismutase.
CONCLUSION: CP/CPPS is accompanied by oxidative stress. Taking Selzinc-plus for two months allows to restore the activity of the antioxidant system.
Full text links
Related Resources
Trending Papers
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease.Pharmaceuticals 2024 March 27
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app